All In Biotech

Drug Trial Radar · NCT02389036

Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients

A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU)

Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 20,010 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,010

Actual

Start

May 1, 2017

Primary completion

Apr 26, 2023

Study completion Apr 26, 2023

Sponsor

Lead sponsor
The George InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Imperial College London; Sunnybrook Health Sciences Centre
First posted
Mar 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Introduction- Hospital acquired infections (HAI) are a major cause of morbidity and mortality and increase health care costs. Critically ill patients are particularly susceptible to these infections and have an even higher mortality. One intervention that has gained much interest in the medical literature for reducing infection rates and deaths from HAIs is selective decontamination of the digestive tract (SDD). SDD involves the application of antibiotic paste to the mouth, throat, stomach and a short course of intravenous antibiotics. The evidence supporting the use of SDD for saving lives and preventing infections is actually quite strong. However, health care professionals in many parts of the world have refrained from using SDD due to fears of the effects of overuse of antibiotics on the frequency of infections with resistant bacteria such as multi-resistant Gram negative organisms, MRSA and Clostridium difficile. SuDDICU is a cross-over, cluster randomised trial comparing the effect of using selective decontamination of the digestive tract (SDD) plus standard care, to standard care alone on hospital mortality in patients receiving mechanical ventilation in the intensive care unit (ICU). Secondary outcomes include an ecological assessment and a long-term health economic analysis.

Conditions

  • Critical Illness
  • Sepsis
  • Septic Shock
  • Ventilator Associated Pneumonia

Interventions

  • SDD Oral PasteDrug

    A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx

  • SDD Gastric SuspensionDrug

    2\. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube

  • Intravenous AntibioticDrug

    A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospital MortalityTime frame: Hospital discharge [up to Day 90 after randomization]

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • The George Institute for Global Health

    Sydney, New South Wales, Australia

  • Sunnybrook Health Sciences Centre

    Toronto, Canada

  • Imperial College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.